Dapagliflozin/saxagliptin

Dapagliflozin/saxagliptin

Combination of
Dapagliflozin	SGLT-2 inhibitor
Saxagliptin	Dipeptidyl peptidase-4 inhibitor
Clinical data
Trade names	Qtern
AHFS/Drugs.com	Professional Drug Facts
License data	US  DailyMed:  Qtern
Pregnancy category	AU:D [1]
Routes of administration	By mouth
ATC code	A10BD21 ( WHO )
Legal status
Legal status	US: ℞-only [2] EU:Rx-only [3]
Identifiers
CAS Number	2446322-16-1
KEGG	D10826

Dapagliflozin/saxagliptin, sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. ^{[2] [3]} It is a combination of dapagliflozin and saxagliptin. ^{[2] [3]} It is taken by mouth. ^{[2] [3]}

The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels). ^[3]

Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017. ^{[3] [4]}

Medical uses

In the United States, dapagliflozin/saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. ^[2]

In the European Union, it is indicated in adults aged 18 years and older with type 2 diabetes:

• to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control. ^[3]
• when already being treated with saxagliptin and dapagliflozin. ^[3]

References

1. "Dapagliflozin / saxagliptin (Qtern) Use During Pregnancy". Drugs.com. 28 June 2019. Archived from the original on 16 July 2020. Retrieved 14 July 2020.
2. "Qtern- dapagliflozin and saxagliptin tablet, film coated". DailyMed. 24 January 2020. Archived from the original on 14 July 2020. Retrieved 14 July 2020.
3. "Qtern EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 14 July 2020. Retrieved 14 July 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
4. "Drug Approval Package: Qtern (dapagliflozin and saxagliptin)". U.S. Food and Drug Administration (FDA). 10 October 2018. Archived from the original on 14 July 2020. Retrieved 14 July 2020.